1
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47 (Suppl):S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bertuccio P, Turati F, Carioli G,
Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends
and predictions in hepatocellular carcinoma mortality. J Hepatol.
67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Singal AG and El-Serag HB: Hepatocellular
carcinoma from epidemiology to prevention: Translating knowledge
into practice. Clin Gastroenterol Hepatol. 13:2140–2151. 2015.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M and Sherman M: Gores: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Cai SH, Lu SX, Liu LL, Zhang CZ and Yun
JP: Increased expression of hepatocyte nuclear factor 4 alpha
transcribed by promoter 2 indicates a poor prognosis in
hepatocellular carcinoma. Therap Adv Gastroenterol. 10:761–771.
2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu
S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic
landscape and genetic heterogeneity in gastric adenocarcinoma
revealed by whole-genome sequencing. Nat Commun. 5:54772014.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Danziger N, Yokoyama M, Jay T, Cordier J,
Glowinski J and Chneiweiss H: Cellular expression, developmental
regulation, and phylogenic conservation of PEA-15, the astrocytic
major phosphoprotein and protein kinase C substrate. J Neurochem.
64:1016–1025. 1995. View Article : Google Scholar : PubMed/NCBI
|
8
|
Greig FH and Nixon GF: Phosphoprotein
enriched in astrocytes (PEA)-15: A potential therapeutic target in
multiple disease states. Pharmacol Ther. 143:265–274. 2014.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Quintavalle C, Di Costanzo S, Zanca C,
Tasset I, Fraldi A, Incoronato M, Mirabelli P, Monti M, Ballabio A,
Pucci P, et al: Phosphorylation-regulated degradation of the
tumor-suppressor form of PED by chaperone-mediated autophagy in
lung cancer cells. J Cell Physiol. 229:1359–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Xie X, Tang H, Pengliu, Kong Y, Wu M, Xiao
X, Yang L, Gao J, Wei W, Lee J, et al: Development of PEA-15 using
a potent non-viral vector for therapeutic application in breast
cancer. Cancer Lett. 356:374–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Crespo-Flores SL, Cabezas A, Hassan S and
Wei Y: PEA-15 C-terminal tail allosterically modulates
death-effector domain conformation and facilitates protein-protein
interactions. Int J Mol Sci. 20:33352019. View Article : Google Scholar
|
12
|
Mace PD, Wallez Y, Egger MF, Dobaczewska
MK, Robinson H, Pasquale EB and Riedl SJ: Structure of ERK2 bound
to PEA-15 reveals a mechanism for rapid release of activated MAPK.
Nat Commun. 4:16812013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Fiory F, Formisano P, Perruolo G and
Beguinot F: Frontiers: PED/PEA-15, a multifunctional protein
controlling cell survival and glucose metabolism. Am J Physiol
Endocrinol Metab. 297:E592–E601. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Besson A, Dowdy SF and Roberts JM: CDK
inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169.
2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Bencivenga D, Caldarelli I, Stampone E,
Mancini FP, Balestrieri ML, Della Ragione F and Borriello A:
p27(Kip1) and human cancers: A reappraisal of a still enigmatic
protein. Cancer Lett. 403:354–365. 2017. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gupta A, Saltarski JM, White MA, Scaglioni
PP and Gerber DE: Therapeutic targeting of nuclear export
inhibition in lung cancer. J Thorac Oncol. 12:1446–1450. 2017.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Peng M, Wang J, Zhang D, Jin H, Li J, Wu
XR and Huang C: PHLPP2 stabilization by p27 mediates its inhibition
of bladder cancer invasion by promoting autophagic degradation of
MMP2 protein. Oncogene. 37:5735–5748. 2018. View Article : Google Scholar : PubMed/NCBI
|
18
|
He W, Wang X, Chen L and Guan X: A
crosstalk imbalance between p27(Kip1) and its interacting molecules
enhances breast carcinogenesis. Cancer Biother Radiopharm.
27:399–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Grimmler M, Wang Y, Mund T, Cilensek Z,
Keidel EM, Waddell MB, Jäkel H, Kullmann M, Kriwacki RW and Hengst
L: Cdk-inhibitory activity and stability of p27Kip1 are directly
regulated by oncogenic tyrosine kinases. Cell. 128:269–280. 2007.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Gallastegui E, Bicer A, Orlando S, Besson
A, Pujol MJ and Bachs O: p27(Kip1) represses the Pitx2-mediated
expression of p21(Cip1) and regulates DNA replication during cell
cycle progression. Oncogene. 36:350–361. 2017. View Article : Google Scholar : PubMed/NCBI
|
21
|
Kim JE and Kang TC: Nucleocytoplasmic
p27(Kip1) export is required for ERK1/2-mediated reactive
astroglial proliferation following status epilepticus. Front Cell
Neurosci. 12:1522018. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhou L, Rui JA, Ye DX, Wang SB, Chen SG
and Qu Q: Edmondson-Steiner grading increases the predictive
efficiency of TNM staging for long-term survival of patients with
hepatocellular carcinoma after curative resection. World J Surg.
32:1748–1756. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Wang GK, Li SH, Zhao ZM, Liu SX, Zhang GX,
Yang F, Wang Y, Wu F, Zhao XX and Xu ZY: Inhibition of heat shock
protein 90 improves pulmonary arteriole remodeling in pulmonary
arterial hypertension. Oncotarget. 7:54263–54273. 2016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Andreozzi M, Quintavalle C, Benz D,
Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F,
Tornillo L, et al: HMGA1 expression in human hepatocellular
carcinoma correlates with poor prognosis and promotes tumor growth
and migration in in vitro models. Neoplasia. 18:724–731. 2016.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH,
Wang H, Cai SH, Yang X, Xie D, Zhang CZ and Yun JP: HBx-mediated
decrease of AIM2 contributes to hepatocellular carcinoma
metastasis. Mol Oncol. 11:1225–1240. 2017. View Article : Google Scholar : PubMed/NCBI
|
26
|
Morofuji N, Ojima H, Hiraoka N, Okusaka T,
Esaki M, Nara S, Shimada K, Kishi Y and Kondo T: Antibody-based
proteomics to identify an apoptosis signature for early recurrence
of hepatocellular carcinoma. Clin Proteomics. 13:282016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Jiang X, Zhang C, Li W, Jiang D, Wei Z, Lv
M, Xie X and Sun X: PEA-15 contributes to the clinicopathology and
AKT-regulated cisplatin resistance in gastric cancer. Oncol Rep.
41:1949–1959. 2019.PubMed/NCBI
|
28
|
Fiory F, Parrillo L, Raciti GA, Zatterale
F, Nigro C, Mirra P, Falco R, Ulianich L, Di Jeso B, Formisano P,
et al: PED/PEA-15 inhibits hydrogen peroxide-induced apoptosis in
Ins-1E pancreatic beta-cells via PLD-1. PLoS One. 9:e1136552014.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Mohammed HN, Pickard MR and
Mourtada-Maarabouni M: The protein phosphatase 4 - PEA15 axis
regulates the survival of breast cancer cells. Cell Signal.
28:1389–1400. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Bartholomeusz C, Rosen D, Wei C, Kazansky
A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J and Ueno NT:
PEA-15 induces autophagy in human ovarian cancer cells and is
associated with prolonged overall survival. Cancer Res.
68:9302–9310. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Lee J, Bartholomeusz C, Krishnamurthy S,
Liu P, Saso H, Lafortune TA, Hortobagyi GN and Ueno NT: PEA-15
unphosphorylated at both serine 104 and serine 116 inhibits ovarian
cancer cell tumorigenicity and progression through blocking
β-catenin. Oncogenesis. 1:e222012. View Article : Google Scholar : PubMed/NCBI
|
32
|
Weijman JF, Riedl SJ and Mace PD:
Structural studies of ERK2 protein complexes. Methods Mol Biol.
1487:53–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
33
|
Quintavalle C, Hindupur SK, Quagliata L,
Pallante P, Nigro C, Condorelli G, Andersen JB, Tagscherer KE, Roth
W, Beguinot F, et al: Phosphoprotein enriched in diabetes
(PED/PEA15) promotes migration in hepatocellular carcinoma and
confers resistance to sorafenib. Cell Death Dis. 8:e31382017.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Hoellein A, Graf S, Bassermann F,
Schoeffmann S, Platz U, Holzlwimmer G, Kröger M, Peschel C,
Oostendorp R, Quintanilla-Fend L and Keller U: Cks1 promotion of S
phase entry and proliferation is independent of p27Kip1
suppression. Mol Cell Biol. 32:2416–2427. 2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Pippa R, Espinosa L, Gundem G,
Garcia-Escudero R, Dominguez A, Orlando S, Gallastegui E, Saiz C,
Besson A, Pujol MJ, et al: p27Kip1 represses transcription by
direct interaction with p130/E2F4 at the promoters of target genes.
Oncogene. 31:4207–4220. 2012. View Article : Google Scholar : PubMed/NCBI
|
36
|
Besson A, Assoian RK and Roberts JM:
Regulation of the cytoskeleton: An oncogenic function for CDK
inhibitors? Nat Rev Cancer. 4:948–955. 2004. View Article : Google Scholar : PubMed/NCBI
|
37
|
Besson A, Gurian-West M, Schmidt A, Hall A
and Roberts JM: p27Kip1 modulates cell migration through the
regulation of RhoA activation. Genes Dev. 18:862–876. 2004.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Shin M, Lee KE, Yang EG, Jeon H and Song
HK: PEA-15 facilitates EGFR dephosphorylation via ERK sequestration
at increased ER-PM contacts in TNBC cells. FEBS Lett.
589:1033–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|